all noted, Our previous publication suggested CRISPR-Cas9 editing at the zygotic stage might unexpectedly introduce a multitude of subtle but unintended mutations, an interpretation that not surprisingly raised numerous questions.
That aside, as a company that is advancing at a rapid pace Crispr has been streamlining its management team lately. enthused, Steve's extensive experience in regulatory strategy and operations across multiple therapeutic areas and geographies will be a tremendous addition to the team.
In monitoring insider transactions, one should analyze the data with the grain of salt.
That being said, we wish to share with you the quote from the Former Fidelity-Magellan Manager (Peter Lynch): “Insiders might sell their shares for any number of reasons, but they buy them for only one they think the price will rise.” Notably, three interesting transactions made our list for the day came from Opko Health (NYSE: OPK), a diversified healthcare company seeking to establish industry-leading positions in large rapidly growing markets. Phillip Frost) has been acquiring shares aggressively over the years.
Instead of elucidating the mystery, this knowledge only rendered it more inexplicable.
Bacteriologist, perform your share in elucidating this difficulty.